BR0109507A - Processo para preparação de forma i, cristalina, de carbegolina - Google Patents

Processo para preparação de forma i, cristalina, de carbegolina

Info

Publication number
BR0109507A
BR0109507A BR0109507-2A BR0109507A BR0109507A BR 0109507 A BR0109507 A BR 0109507A BR 0109507 A BR0109507 A BR 0109507A BR 0109507 A BR0109507 A BR 0109507A
Authority
BR
Brazil
Prior art keywords
cabergoline
crystalline form
carbegoline
preparation
crystalline
Prior art date
Application number
BR0109507-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Attilio Tomasi
Stefania Magenes
Giuliano Rammella
Mario Ungari
Gianfranco Pallanza
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0109507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0109507A publication Critical patent/BR0109507A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0109507-2A 2000-03-24 2001-03-19 Processo para preparação de forma i, cristalina, de carbegolina BR0109507A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (1)

Publication Number Publication Date
BR0109507A true BR0109507A (pt) 2002-12-10

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109507-2A BR0109507A (pt) 2000-03-24 2001-03-19 Processo para preparação de forma i, cristalina, de carbegolina

Country Status (31)

Country Link
US (2) US6727363B2 (enExample)
EP (1) EP1272489B1 (enExample)
JP (1) JP4184666B2 (enExample)
KR (1) KR100827558B1 (enExample)
CN (1) CN1188412C (enExample)
AR (1) AR032449A1 (enExample)
AT (1) ATE250601T1 (enExample)
AU (2) AU780747B2 (enExample)
BR (1) BR0109507A (enExample)
CA (1) CA2402836A1 (enExample)
CZ (1) CZ20023176A3 (enExample)
DE (1) DE60100858T2 (enExample)
DK (1) DK1272489T3 (enExample)
EA (1) EA005928B1 (enExample)
EE (1) EE05088B1 (enExample)
ES (1) ES2208602T3 (enExample)
GB (1) GB0007308D0 (enExample)
HK (1) HK1052348B (enExample)
HU (1) HUP0300591A3 (enExample)
IL (2) IL150985A0 (enExample)
MX (1) MXPA02009283A (enExample)
MY (1) MY134189A (enExample)
NO (1) NO20024321L (enExample)
NZ (1) NZ521316A (enExample)
PE (1) PE20011140A1 (enExample)
PL (1) PL358253A1 (enExample)
PT (1) PT1272489E (enExample)
SI (1) SI1272489T1 (enExample)
SK (1) SK13582002A3 (enExample)
WO (1) WO2001070740A1 (enExample)
ZA (1) ZA200206045B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04008935A (es) * 2002-03-15 2004-11-26 Pharmacia Corp Procedimiento para la preparacion de la forma i cristalina de la cabergolina.
US20060281777A1 (en) * 2002-03-15 2006-12-14 Pfizer Inc. Process for preparing crystalline form I of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
KR20060028761A (ko) * 2003-05-08 2006-04-03 아이박스 파마슈티컬스 에스.알.오. 다형의 카베르골린
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
EP2185169A2 (en) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
AU680539B2 (en) 1993-08-18 1997-07-31 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
WO1999036095A1 (en) 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
EP1066038B1 (en) 1998-03-27 2005-12-21 Pharmacia & Upjohn Company LLC Use of cabergoline in the treatment of restless legs syndrome
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline

Also Published As

Publication number Publication date
CZ20023176A3 (cs) 2003-02-12
CN1419554A (zh) 2003-05-21
NO20024321D0 (no) 2002-09-10
EP1272489B1 (en) 2003-09-24
ES2208602T3 (es) 2004-06-16
AU2005203071B2 (en) 2007-10-18
DK1272489T3 (da) 2003-12-15
WO2001070740A1 (en) 2001-09-27
KR20020081587A (ko) 2002-10-28
AU780747B2 (en) 2005-04-14
EA200201016A1 (ru) 2003-02-27
GB0007308D0 (en) 2000-05-17
JP2003528100A (ja) 2003-09-24
DE60100858D1 (de) 2003-10-30
CN1188412C (zh) 2005-02-09
ATE250601T1 (de) 2003-10-15
NZ521316A (en) 2004-05-28
PE20011140A1 (es) 2001-11-01
HUP0300591A2 (hu) 2003-07-28
US6727363B2 (en) 2004-04-27
IL150985A0 (en) 2003-02-12
CA2402836A1 (en) 2001-09-27
PT1272489E (pt) 2004-02-27
MY134189A (en) 2007-11-30
US20030149067A1 (en) 2003-08-07
HK1052348B (zh) 2005-09-16
EP1272489A1 (en) 2003-01-08
US20040092744A1 (en) 2004-05-13
JP4184666B2 (ja) 2008-11-19
HUP0300591A3 (en) 2009-01-28
DE60100858T2 (de) 2004-07-29
EE200200545A (et) 2004-04-15
EE05088B1 (et) 2008-10-15
SI1272489T1 (en) 2004-02-29
AU2005203071A1 (en) 2005-08-11
HK1052348A1 (en) 2003-09-11
SK13582002A3 (sk) 2003-04-01
MXPA02009283A (es) 2003-03-12
EA005928B1 (ru) 2005-08-25
AR032449A1 (es) 2003-11-12
US6953854B2 (en) 2005-10-11
KR100827558B1 (ko) 2008-05-07
AU6211001A (en) 2001-10-03
ZA200206045B (en) 2003-07-29
PL358253A1 (en) 2004-08-09
NO20024321L (no) 2002-09-10
IL150985A (en) 2007-03-08

Similar Documents

Publication Publication Date Title
BR0109507A (pt) Processo para preparação de forma i, cristalina, de carbegolina
CR6368A (es) Nuevos esteres derivados de compuestos fenil-ciclohexil sustituidos
PL377196A1 (pl) Sposób przygotowania i postacie krystaliczne enancjomerów optycznych modafinilu
WO2007137030A3 (en) Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
EA200802385A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 11β-(4-АЦЕТИЛФЕНИЛ)-20,20,21,21,21-ПЕНТАФТОР-17-ГИДРОКСИ-19-НОР-17A-ПРЕГНА-4,9-ДИЕН-3-ОНА
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
WO2004091504A3 (en) Substituted quinobenzoxazine analogs
WO2006113509A3 (en) Quinobenzoxazine analogs and methods of using thereof
HUP0100160A2 (hu) Módosított cellulóz-éterek, előállításuk, valamint e vegyületeket tartalmazó kompozíciók
UA72895C2 (uk) Нова кристалічна модифікація n торасеміду
BR0301667A (pt) Processo para a preparação de polìmeros em emulsão com pureza elevada
AR037005A1 (es) Derivados de acidos dimetilfenilaceticos, derivados de piperidina, y proceso para la produccion de derivados de piperidina.
AR027559A1 (es) Metodo para la preparacion de citalopram
NO20004919D0 (no) FremgangsmÕte for fremstilling av 5-hydroksybenzo[b]tiofen-3- karboksylsyrederivater
PT1102765E (pt) Processo para a sintese de derivados de (1h)-benzo¬c|quinolizin-3-onas
EP1390343A4 (en) NOVEL RETINOID DERIVATIVES, METHODS FOR PREPARING THESE COMPOUNDS, AND ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EA200201236A1 (ru) Новый полиморф v торасемида
EA200201003A1 (ru) Аморфная модификация торасемида
BR9806875A (pt) Processo para a preparação de um composto.
BR0308472A (pt) Processo para preparar a forma i cristalina de cabergolina
EA200300400A1 (ru) 17α-ФТОРАЛКИЛСТЕРОИДЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
WO1999044985A3 (en) SYNTHESIS OF CHIRAL β-AMINO ACIDS
EP1408036A4 (en) METHOD FOR PRODUCING BENZOFURAN DERIVATIVES
BR0112876A (pt) Processo para preparação de discodermolida e seus análogos
DE69935250D1 (de) Oleandomycin-derivate

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.